, /PRNewswire/ -- The global sciatica treatment market size is estimated to grow by from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of 4.83% during the forecast period.
Rising awareness about sciatica is driving market growth, with a trend towards development of clonidine micropellet epidural injections. However, lack of approved treatments poses a challenge. Key market players include Amneal Pharmaceuticals Inc.
, Apotex Inc., Aurobindo Pharma Ltd., Bayer AG, Dr Reddys Laboratories Ltd.
, Elam Pharma Pvt. Ltd., Fresenius SE and Co.
KGaA, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Johnson and Johnson, KOLON LIFE SCIENCE, Lupin Ltd., Novartis AG, Omega Laser Systems Ltd.
, Ozone Pharmaceuticals Ltd., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd.
, Teva Pharmaceutical Industries Ltd., and Viatris Inc..
Get a detailed analysis on regions, market segments, customer landscape, and companies - The sciatica treatment market is witnessing innovation with the development of micropellet technology-based nonsteroidal epidural injections. Currently, no FDA-approved steroids exist for sciatica treatment, and off-label steroid preparations have limitations due to associated side effects. Sollis Therapeutics is leading this innovation with a Phase III clinical trial on clonidine micropellets for sciatica pain relief in adults.
This technology enables targeted delivery of medication to affected nerves, potentially improving safety and ef.
